Combined MEK and YAP inhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease

The cure rate of high-risk neuroblastoma remains unsatisfactory, necessitating the development of novel therapies. We previously reported the in vitro and in vivo efficacy of trametinib (TR), a MEK inhibitor, in neuroblastoma. The administration of TR further prolonged survival in a mouse model of neuroblastoma with minimal residual disease (MRD), which mimics post-tumorectomy residuals. However, the acquisition of resistance to long-term TR administration with YAP activation in the Hippo pathway remains an issue.